Title
After-discharges and seizures during pediatric extra-operative electrical cortical stimulation functional brain mapping: Incidence, thresholds, and determinants
Date Issued
01 October 2017
Access level
metadata only access
Resource Type
journal article
Author(s)
Aungaroon G.
Horn P.S.
Byars A.W.
Greiner H.M.
Tenney J.R.
Arthur T.M.
Crone N.E.
Holland K.D.
Mangano F.T.
Arya R.
Cincinnati Children's Hospital Medical Center
Publisher(s)
Elsevier Ireland Ltd
Abstract
Objective This study examined the incidence, thresholds, and determinants of electrical cortical stimulation (ECS)-induced after-discharges (ADs) and seizures. Methods Electrocorticograph recordings were reviewed to determine incidence of ECS-induced ADs and seizures. Multivariable analyses for predictors of AD/seizure occurrence and their thresholds were performed. Results In 122 patients, the incidence of ADs and seizures was 77% (94/122) and 35% (43/122) respectively. Males (odds ratio [OR] 2.92, 95% CI 1.21–7.38, p = 0.02) and MRI-negative patients (OR 3.69, 95% CI 1.24–13.7, p = 0.03) were found to have higher odds of ECS-induced ADs. A significant trend for decreasing AD thresholds with age was seen (regression co-efficient −0.151, 95% CI −0.267 to −0.035, p = 0.011). ECS-induced seizures were more likely in patients with lateralized functional imaging (OR 6.62, 95% CI 1.36–55.56, p = 0.036, for positron emission tomography) and presence of ADs (OR 3.50, 95% CI 1.12–13.36, p = 0.043). Conclusions ECS is associated with a high incidence of ADs and seizures. With age, current thresholds decrease and the probability for AD/seizure occurrence increases. Significance ADs and seizures during ECS brain mapping are potentially hazardous and affect its functional validity. Thus, safer method(s) for brain mapping with improved neurophysiologic validity are desirable.
Start page
2078
End page
2086
Volume
128
Issue
10
Language
English
OCDE Knowledge area
Neurología clínica
Subjects
Scopus EID
2-s2.0-85026542579
PubMed ID
Source
Clinical Neurophysiology
ISSN of the container
13882457
Sponsor(s)
Disclosures: RA receives research support from Pediatric Epilepsy Research Foundation (Co-I). KDH receives funding from the following NIH grants: R01 NS062756 (PI), R01 NS062806 (Co-I), and R01 NS065020 (Co-I). Other co-authors do not have any pertinent disclosures.
Sources of information:
Directorio de Producción Científica
Scopus